Five Prime Therapeutics (FPRX) to present at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

• Headquarters: San Francisco, CA
• Founded: December 2001
• fiveprime.com

   

Five Prime Therapeutics announces Cabiralizumab Phase 1a/1b data abstract selected for late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

• The abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, has been selected for a late breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland. Abstract Title: "First in Human Phase I Dose Escalation and Expansion of a novel combination, anti-CSF1-receptor (cabiralizumab) plus anti-PD-1 (nivolumab) in patients with advanced solid tumors."
• This will be the first presentation of clinical data on a combination of a CSF-1R antibody and a checkpoint inhibitor, to the Company's knowledge 
• In the Phase 1a/1b trial, Five Prime and Bristol-Myers Squibb are evaluating the safety, tolerability and preliminary efficacy of the combination in advanced solid tumors.